A detailed history of Hbk Sorce Advisory LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Hbk Sorce Advisory LLC holds 40,962 shares of GILD stock, worth $3.87 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
40,962
Previous 43,445 5.72%
Holding current value
$3.87 Million
Previous $2.98 Million 15.2%
% of portfolio
0.13%
Previous 0.11%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$66.59 - $83.99 $165,342 - $208,547
-2,483 Reduced 5.72%
40,962 $3.43 Million
Q2 2024

Aug 08, 2024

BUY
$63.15 - $72.88 $414,011 - $477,801
6,556 Added 17.77%
43,445 $2.98 Million
Q1 2024

May 09, 2024

BUY
$71.58 - $87.29 $135,429 - $165,152
1,892 Added 5.41%
36,889 $2.7 Million
Q4 2023

Jan 25, 2024

BUY
$73.27 - $83.09 $212,336 - $240,794
2,898 Added 9.03%
34,997 $2.84 Million
Q3 2023

Nov 06, 2023

BUY
$73.94 - $80.67 $70,390 - $76,797
952 Added 3.06%
32,099 $2.41 Million
Q2 2023

Aug 04, 2023

SELL
$76.01 - $86.7 $2.7 Million - $3.08 Million
-35,483 Reduced 53.25%
31,147 $2.4 Million
Q1 2023

Aug 15, 2023

BUY
$77.31 - $88.08 $185,080 - $210,863
2,394 Added 7.69%
33,541 $2.78 Million
Q1 2023

May 15, 2023

SELL
$77.31 - $88.08 $375,262 - $427,540
-4,854 Reduced 6.79%
66,630 $8.38 Million
Q4 2022

Feb 09, 2023

BUY
$62.32 - $89.47 $2.23 Million - $3.21 Million
35,861 Added 100.67%
71,484 $6.14 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $116,996 - $133,639
1,965 Added 5.84%
35,623 $2.2 Million
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $57,200 - $64,424
-991 Reduced 2.86%
33,658 $2.08 Million
Q1 2022

May 13, 2022

BUY
$57.92 - $72.58 $202,720 - $254,030
3,500 Added 11.24%
34,649 $2.06 Million
Q4 2021

Feb 15, 2022

BUY
$64.88 - $73.64 $38,214 - $43,373
589 Added 1.93%
31,149 $2.26 Million
Q3 2021

Nov 15, 2021

SELL
$67.69 - $73.03 $12,116 - $13,072
-179 Reduced 0.58%
30,560 $2.14 Million
Q2 2021

Aug 12, 2021

BUY
$63.47 - $69.35 $20,056 - $21,914
316 Added 1.04%
30,739 $2.12 Million
Q1 2021

May 14, 2021

BUY
$60.0 - $68.46 $391,680 - $446,906
6,528 Added 27.32%
30,423 $1.97 Million
Q4 2020

Feb 12, 2021

BUY
$56.65 - $64.55 $324,604 - $369,871
5,730 Added 31.54%
23,895 $1.39 Million
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $152,207 - $191,374
2,451 Added 15.6%
18,165 $1.15 Million
Q2 2020

Aug 14, 2020

BUY
$72.34 - $84.0 $94,693 - $109,956
1,309 Added 9.09%
15,714 $1.21 Million
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $122,128 - $156,429
1,950 Added 15.66%
14,405 $1.08 Million
Q4 2019

Feb 13, 2020

BUY
$61.62 - $67.78 $36,725 - $40,396
596 Added 5.03%
12,455 $809,000
Q3 2019

Nov 14, 2019

BUY
$62.51 - $69.0 $16,752 - $18,492
268 Added 2.31%
11,859 $752,000
Q2 2019

Aug 15, 2019

SELL
$61.87 - $69.38 $254,780 - $285,706
-4,118 Reduced 26.21%
11,591 $783,000
Q2 2019

Aug 14, 2019

BUY
$61.87 - $69.38 $182,145 - $204,254
2,944 Added 23.06%
15,709 $1.31 Million
Q1 2019

May 13, 2019

BUY
$62.53 - $70.05 $127,561 - $142,902
2,040 Added 19.02%
12,765 $830,000
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $67,623 - $88,243
1,117 Added 11.63%
10,725 $671,000
Q3 2018

Nov 15, 2018

SELL
$71.28 - $78.92 $29,224 - $32,357
-410 Reduced 4.09%
9,608 $742,000
Q2 2018

Aug 10, 2018

SELL
$64.88 - $75.68 $44,183 - $51,538
-681 Reduced 6.37%
10,018 $0
Q1 2018

May 15, 2018

BUY
$72.84 - $88.8 $122,079 - $148,828
1,676 Added 18.57%
10,699 $807,000
Q4 2017

Feb 15, 2018

SELL
$71.15 - $83.52 $14,728 - $17,288
-207 Reduced 2.24%
9,023 $646,000
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $665,575 - $788,888
9,230
9,230 $748,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Hbk Sorce Advisory LLC Portfolio

Follow Hbk Sorce Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hbk Sorce Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hbk Sorce Advisory LLC with notifications on news.